Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Payables: 2023-2024

Historic Payables for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $18.8 million.

  • Monte Rosa Therapeutics' Payables rose 18.56% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.7 million, marking a year-over-year increase of 25.52%. This contributed to the annual value of $18.8 million for FY2024, which is 28.66% up from last year.
  • As of FY2024, Monte Rosa Therapeutics' Payables stood at $18.8 million, which was up 28.66% from $14.6 million recorded in FY2023.
  • Monte Rosa Therapeutics' Payables' 5-year high stood at $18.8 million during FY2024, with a 5-year trough of $14.6 million in FY2023.
  • Moreover, its 2-year median value for Payables was $16.7 million (2023), whereas its average is $16.7 million.
  • Data for Monte Rosa Therapeutics' Payables shows a peak YoY increased of 28.66% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Monte Rosa Therapeutics' Payables stood at $14.6 million in 2023, then rose by 28.66% to $18.8 million in 2024.